Resumen
O presente artigo busca aprofundar o entendimento das vantagens competitivas sustentadas construídas através das estratégias de investimentos em P&D e de registros de patentes e trademarks pela Big Pharma, à luz dos três grupos de atividades principais relacionados às capacitações dinâmicas: identificar, aproveitar e transformar. A utilização deste arcabouço contribui para o entendimento das estratégias de P&D, patentes e trademarks pela Big Pharma na criação de vantagens competitivas sustentáveis e na permanência e estabilidade dessas empresas como líderes do setor. A identificação de oportunidades de P&D que despontam do setor público, a capacidade de aproveitar as oportunidades identificadas através de competências organizacionais e as estratégias constantes de transformação de recursos – como o evergreening – e a construção de marcas fortes foram identificadas como parte importante das capacitações dinâmicas dessas firmas que possibilitam a criação e manutenção de vantagens competitivas sustentáveis.
Citas
ABBAS, M. Z. Evergreening of pharmaceutical patents: a blithe disregard for the rationale of the patent system. Journal of Generic Medicines, London, v. 15, n. 2, p. 53-60, 2019.
ALVES, F. C.; BOMTEMPO, J. V.; COUTINHO, P. L. A. Competências para Inovar na Indústria Petroquímica Brasileira. Revista Brasileira de Inovação, Campinas, v. 4, n. 2, p. 301-327, 2009.
AL-ZAWAHREH, A.; MAHMOUD, A. R.; ALKHAWALDEH, A. M. The impact of corporate social responsibility on the performance of pharmaceutical companies in Jordan. International Journal of Business and Social Science, New York, v. 9, n. 12, p. 41-47, 2018.
AMAYA, N. et al. Role of internal resources on the competitive advantage building in a knowledge-intensive organisation in an emerging market. VINE Journal of Information and Knowledge Management Systems, Bingley, 2022. No prelo.
AMOROSO, S. et al. World corporate top R&D investors: paving the way to climate neutrality. Luxembourg: Publications Office of the European Union, 2021. Disponível em: <https://data.europa.eu/doi/10.2760/49552>. Acesso em: 22 jun. 2023.
ANGELL, M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House, 2005.
BARNEY, J. B.; MACKEY, T. B. Testing resource-based theory. Research Methodology in Strategy and Management, Bingley, v. 2, p. 1-13, 2005.
BARNEY, J. B.; MACKEY, A. Monopoly profits, efficiency profits, and teaching strategic management. Academy of Management Learning & Education, Briarcliff Manor, v. 17, n. 3, p. 359-373, 2018.
BARNEY, J. B.; KETCHEN, D. J.; WRIGHT, M. Resource-based theory and the value creation framework. Journal of Management, Thousand Oaks, v. 47, n. 7, p. 1936-1955, 2021.
BLACKETT, T.; HARRISON, T. Brand medicine: use and future potential of branding in pharmaceutical markets. International Journal of Medical Marketing, Thousand Oaks, v. 2, n. 1, p. 33-49, 2001.
BRANDENBURGER, A.; STUART, H. Value-based business strategy. Journal of Economics & Management Strategy, Cambridge, v. 5, n. 1, p. 5-24, 1996.
BUSFIELD, J. Globalization and the pharmaceutical industry revisited. International Journal of Health Services, Connecticut, v. 33, n. 3, p. 581-605, 2003.
CARRICK, J. From Penrose to complementary assets: the evolution of the resource-based literature. Journal of Management Policy and Practice, Florida, v. 14, n. 3, p. 125-156, 2013.
CHANG, J. et al. Prescription to over-the-counter switches in the United States. Journal of Management Policy and Practice, Florida, v. 5, n. 3, p. 149-154, 2016.
CHUDNOVSKY, D. Patents and trademarks in pharmaceuticals. World Development, New York, v. 11, n. 3, p. 187-193, 1983.
CLEARY, E. et al. Contribution of NIH funding to new drug approvals 2010-2016. Proceedings of the National Academy of Sciences, Washington, v. 115, n. 10, p. 2329-2334, 2018.
COMANOR, W. S.; SCHERER, F. M. Mergers and innovation in the pharmaceutical industry. Journal of Health Economics, Amsterdam, v. 32, n. 1, p. 106-113, 2013.
DE STEFANO, M. C.; MONTES-SANCHO, M. J.; BUSCH, T. A natural resource-based view of climate change: Innovation challenges in the automobile industry. Journal of Cleaner Production, Karlsruhe, v. 139, p. 1436-1448, 2016.
DIMASI, J. A.; GRABOWSKI, H. G.; HANSEN, R. W. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, Rotterdam, v. 47, p. 20-33, 2016.
DOSI, G. et al. Big Pharma and monopoly capitalism: a long-term view. Structural Change and Economic Dynamics, Oxford, v. 65, p. 15-35, 2023.
DUARTE ALONSO, A. Exploring a developing tourism industry: a resource-based view approach. Tourism Recreation Research, Abingdon, v. 42, n. 1, p. 45-58, 2017.
EISENHARDT, K. M.; MARTIN, J. A. Dynamic capabilities: what are they? Strategic Management Journal, Chichester, v. 21, n. 10-11, p. 1105-1121, 2000. Disponível em: <https://data.europa.eu/doi/10.2760/49552>. Acesso em: 22 jun. 2023.
FELDMAN, R. May your drug price be evergreen. Journal of Law and the Biosciences, Oxford, v. 5, n. 3, p. 590-647, 2018.
GANUZA, J.-J.; LLOBET, G.; DOMÍNGUEZ, B. R&D in the pharmaceutical industry: A world of small innovations. Management Science, Maryland, v. 55, n. 4, p. 539-551, 2009.
GAUTAM, A.; PAN, X. The changing model of big pharma: impact of key trends. Drug Discovery Today, Kidlington, v. 21, n. 3, p. 379-384, 2016.
HENDERSON, R.; COCKBURN, I. Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management Journal, Chichester, v. 15, n. S1, p. 63-84, 1994.
HOLDFORD, D. A. Resource-based theory of competitive advantage: a framework for pharmacy practice innovation research. Pharmacy Practice, Colômbia, v. 16, n. 3, p. 1351, 2018.
HOSSAIN, M. S. et al. Determinants of sustainable competitive advantage from resource-based view: implications for hotel industry. Journal of Hospitality and Tourism Insights, Bingley, v. 5, n. 1, p. 79-98, 2022.
JAMES, A. D. The strategic management of mergers and acquisitions in the pharmaceutical industry: developing a resource-based perspective. Technology Analysis & Strategic Management, Abingdon, v. 14, n. 3, p. 299-313, 2002.
KAYO, E. et al. Ativos intangíveis, ciclo de vida e criação de valor. Revista de Administração Contemporânea, São Paulo, v. 10, n. 3, p. 73-90, 2006.
KESSELHEIM, A. S. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences: review of legislation affecting drug development. Milbank Quarterly, New York, v. 89, n. 3, p. 450-502, 2011.
KNOTT, A. M.; BRYCE, D. J.; POSEN, H. E. On the strategic accumulation of intangible assets. Organization Science, Providence, v. 14, n. 2, p. 192-207, 2003.
LADHA, Z. Marketing strategy: are consumers really influenced by brands when purchasing pharmaceutical products? Journal of Medical Marketing, Thousand Oaks, v. 7, n. 2, p. 146-151, 2007.
LAZONICK, W.; MAZZUCATO, M. The risk-reward nexus in the innovation-inequality relationship: who takes the risks? Who gets the rewards? Industrial and Corporate Change, Oxford, v. 22, n. 4, p. 1093-1128, 2013.
MALERBA, F.; ORSENIGO, L. The evolution of the pharmaceutical industry. Business History, London, v. 57, n. 5, p. 664-687, 2015.
MAZZUCATO, M. The entrepreneurial state: debunking public vs. private sector myths. London: Anthem Press, 2013.
MAZZUCATO, M. The value of everything: making and taking in the global economy. London: Penguin, 2018.
MAZZUCATO, M.; ROY, V. Rethinking value in health innovation: from mystifications towards prescriptions. Journal of Economic Policy Reform, Reino Unido, v. 22, n. 2, p. 101-119, 2019.
MERCADANTE, E.; PARANHOS, J. Pharmaceutical patent term extension and patent prosecution in Brazil (1997-2018). Cadernos de Saúde Pública, Rio de Janeiro, v. 38, n. 1, p. 1-13, 2022.
PARANHOS, J.; MERCADANTE, E.; HASENCLEVER, L. Os esforços inovativos das grandes empresas farmacêuticas no Brasil. Revista Brasileira de Inovação, Campinas, v. 19, e0200015, 2020.
PENROSE, E. The theory of the growth of the firm. Oxford: Oxford University Press, 1959.
PENROSE, E. Foreign investment and the growth of the firm. The Economic Journal, Nashville, v. 45, n. 2, p. 531-543, 1995.
PENROSE, E. Limits to the growth and size of firms. The American Economic Review, Rio de Janeiro, v. 38, n. 1, p. 1-13, 2022.
PETERAF, M. A. The cornerstones of competitive advantage: a resource-based view. Strategic Management Journal, Chichester, v. 14, n. 3, p. 179-191, 1993.
PROGOULAKI, M.; THEOTOKAS, I. Human resource management and competitive advantage: an application of resource-based view in the shipping industry. Marine Policy, Amsterdam, v. 34, n. 3, p. 575-582, 2010.
SAMPAT, B. N.; LICHTENBERG, F. R. What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Affairs, Millwood, v. 30, n. 2, p. 332-339, 2011.
SANTOS, T. The impact of RBV on value creation in the pharmaceutical industry. 2023. (Dissertação Mestrado) - Instituto Universitário de Lisboa, Lisboa, 2023.
SCHERER, F. M. Pharmaceutical Innovation. In: HALL, B. H.; ROSENBERG, N. (Org.). Handbook of the economics of innovation. Amsterdam: Elsevier, 2010. v. 1, p. 539-574.
SIMARMATA, M.; SINAGA, S. S.; MUDA, I. The management company intangible assets governance in pharmaceutical industry. Journal of Pharmaceutical Negative Results, Mumbai, v. 13, n. 3, p. 1628-1630, 2022.
TEECE, D. J. Explicating dynamic capabilities: the nature and microfoundations of (sustainable) enterprise performance. Strategic Management Journal, Chichester, v. 28, n. 13, p. 1319-1350, 2007.
TEECE, D. J. Technological innovation and the theory of the firm. In: HALL, B. H.; ROSENBERG, N. (Org.). Handbook of the economics of innovation. Amsterdam: Elsevier, 2010. v. 1, p. 679-730.
TEECE, D. J. Towards a capability theory of (innovating) firms: implications for management and policy. Cambridge Journal of Economics, Oxford, v. 41, n. 3, p. 693-720, 2017.
TEECE, D. J.; PISANO, G.; SHUEN, A. Dynamic capabilities and strategic management. Strategic Management Journal, Chichester, v. 18, n. 7, p. 509-533, 1997.
TOMA, S. G.; STEFAN, C. Big Pharma, big business. Strategic Management Journal, Chichester, v. 18, n. 7, p. 509-533, 1997.
WERNERFELT, B. A resource-based view of the firm. “Ovidius” University Annals, Economic Sciences Series, Constanta, v. 21, n. 1, p. 677-683, 2021.
WIBOWO, A.; HANDIKA, R. F. The strategy of the banking industry in Indonesia: following institutional theory or resource-based view? Jurnal Siasat Bisnis, Yogyakarta, v. 21, n. 2, p. 131-141, 2017.
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Derechos de autor 2024 Revista Brasileira de Inovação
Descargas
